Business Context and Reporting Period
Company: IMPACT BIOMEDICAL INC.
Filing Type: Form 8-K (Current Report)
Date of Report: March 24, 2025
Event: Entry into a Material Definitive Agreement (Debt Conversion Agreement) with DSS, Inc.
Key Financial Metrics
This filing reports on a specific debt restructuring event rather than periodic financial performance. Key figures include:
- Total Promissory Note Balance (as of March 24, 2025): $13,176,477.03
- Original Principal Amount: $12,000,000
- Debt Settled via Conversion: $8,697,142.80
- Shares Issued for Settlement: 2,415,873 shares of Common Stock
- Conversion Price: $3.60 per share (equal to closing market price on March 24, 2025)
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or remaining liquidity outside of the specific debt transaction details.
Material Changes
The Company executed a partial settlement of indebtedness under an Amended and Restated Promissory Note dated September 16, 2024. Approximately 66% of the outstanding principal balance ($8,697,142.80 of $13,176,477.03) was converted into equity, reducing the Company's debt load while increasing the number of outstanding shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the disclosure of the debt conversion itself. The transaction was structured at the prevailing market price, suggesting an alignment with current market valuation for the settlement.
Investor Verification Checklist
- Verify the remaining outstanding balance on the Promissory Note after the $8.7M conversion.
- Confirm the total number of authorized and outstanding shares post-issuance to assess dilution impact.
- Review the terms of the Amended and Restated Promissory Note (dated September 16, 2024) for any remaining interest obligations or maturity dates.
- Check subsequent filings for the impact of this equity issuance on the Company's capitalization table.